Press Releases Keyword Search Year None202120202019201820172016201520142013 May 5, 2021 Editas Medicine Announces First Quarter 2021 Results and Update May 5, 2021 Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer May 4, 2021 Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting May 1, 2021 Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting April 28, 2021 Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update February 25, 2021 Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update February 18, 2021 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update February 8, 2021 Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer January 20, 2021 Editas Medicine Announces Pricing of Offering of Common Stock January 19, 2021 Editas Medicine Announces Offering of Common Stock Pagination Current page 1 Page 2 Next page next › Last page last »
May 4, 2021 Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting
May 1, 2021 Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting
April 28, 2021 Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update
February 18, 2021 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update
